|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 David Geffen School of Medicine at UCLA
2 Mayo Medical and Graduate Schools of Medicine
* To whom correspondence should be addressed. E-mail: AMatveyenko{at}mednet.ucla.edu.
It has previously been shown that insulin is secreted in discrete secretory bursts by sampling directly from the portal vein in the dog and humans. Deficient pulsatile insulin secretion is the basis for impaired insulin secretion in type 2 diabetes. However, while novel genetically modified disease models of diabetes are being developed in rodents, no validated method for quantifying pulsatile insulin secretion has been established for rodents. To address this we 1) developed a novel rat model with chronically implanted portal vein catheters, 2) established the parameters to permit deconvolution of portal vein insulin concentrations profiles to measure insulin secretion and resolve its pulsatile components, 3) measured total and pulsatile insulin secretion in comparison to that in the dog, the species in which this sampling and deconvolution approach was validated for quantifying pulsatile insulin secretion. In rats, portal vein catheter patency and function was maintained for periods up to 2-3 weeks with no post-operative complications such as catheter tract infection. Rat portal vein insulin concentration profiles in the fasting state revealed distinct insulin oscillations with a periodicity of ~5 minutes and an amplitude of up to 600 pmol/l which was remarkably similar to that in the dogs and in humans. Deconvolution analysis of portal vein insulin concentrations reveled that the majority of insulin (~70%) in the rat is secreted in distinct insulin pulses occurring at ~5 minute intervals. This model therefore permits direct accurate measurments of pulsatile insulin secretion in a relatively inexpensive animal and with increased introduction of genetically modified rat models, will be an important tool in elucidating underlying mechanisms of impaired pulsatile insulin secretion in diabetes.
This article has been cited by other articles:
![]() |
A. V. Matveyenko, S. Dry, H. I. Cox, A. Moshtaghian, T. Gurlo, R. Galasso, A. E. Butler, and P. C. Butler Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions With Metformin Diabetes, July 1, 2009; 58(7): 1604 - 1615. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Matveyenko, T. Gurlo, M. Daval, A. E. Butler, and P. C. Butler Successful Versus Failed Adaptation to High-Fat Diet-Induced Insulin Resistance: The Role of IAPP-Induced {beta}-Cell Endoplasmic Reticulum Stress Diabetes, April 1, 2009; 58(4): 906 - 916. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Matveyenko, J. D. Veldhuis, and P. C. Butler Adaptations in pulsatile insulin secretion, hepatic insulin clearance, and {beta}-cell mass to age-related insulin resistance in rats Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E832 - E841. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |